Earnings review - Boston scientific (BSX) Q2 2026
Muffett Investments
Earnings Watch · Stock Analysis Division
Earnings Review
29 July 2026
◆ Healthcare · Medical Devices
Boston Scientific Corporation
Report Period
Q2 FY2026
Reported: 2026-07-29
Headline
Strong Beat
→ Revenue & EPS Beat
Key Metrics at a Glance
Net Sales
$5.442B
+7.5% YoY (vs $5.37B est)
Adjusted EPS
$0.86
+11.7% YoY (vs $0.83 est)
Cardiovascular
$3.580B
+8.3% YoY (+7.8% Organic)
MedSurg Sales
$1.862B
+5.9% YoY (+5.4% Organic)
FY26 EPS Guide
$3.28 - $3.32
vs $3.36 Consensus Est
Financial Metrics — Detailed Breakdown
| Metric | Q2 FY2026 | Q2 FY2025 | YoY Change | Consensus Est. | vs. Estimate |
|---|---|---|---|---|---|
| Net Sales | $5,442M | $5,062M | +7.5% | $5,370M | BEAT |
| Cardiovascular Segment | $3,580M | $3,306M | +8.3% | — | BEAT |
| MedSurg Segment | $1,862M | $1,758M | +5.9% | — | BEAT |
| Organic Sales Growth | 7.0% | 6.2% | +80bps | 5.8% | BEAT |
| Adjusted EPS | $0.86 | $0.77 | +11.7% | $0.83 | BEAT |
| GAAP Net Income (Per Share) | $0.61 | $0.51 | +19.6% | — | N/A |
| Full-Year 2026 EPS Guidance | $3.28 – $3.32 | $3.00 – $3.05 | +9.0% | $3.36 | BELOW |
| Full-Year Organic Growth Guide | ~5% – 6% | ~5% – 6% | Inline | ~5.2% | INLINE |
⚠ Management Commentary & Operational Highlights
-
FARAPULSE & WATCHMAN Innovation Leadership High-margin adoption of FARAPULSE Pulsed Field Ablation (PFA) and WATCHMAN FLX LAAC devices accelerated electrophysiology momentum across global markets.
-
Conservative Forward Guidance Full-year adjusted EPS guidance range of $3.28 to $3.32 sits slightly below the $3.36 Wall Street consensus, reflecting prudent macroeconomic and foreign exchange assumptions.
📈 Stock Performance Context
Ticker
BSX
NYSE Listed
Sector
Medical Devices
Healthcare Leader
Q2 Adj. EPS Beat
+$0.03
$0.86 vs $0.83 est
Q2 Sales Beat
+$72M
$5.442B vs $5.37B est
Boston Scientific's core structural heart and electrophysiology franchises continue to outpace broader medtech market growth rates.
Our Verdict
Strong Beat
Boston Scientific reported a robust Q2 FY2026 performance, surpassing Wall Street expectations on both net sales ($5.442B, +7.5% YoY) and adjusted EPS ($0.86, +11.7% YoY). Growth was anchored by an 8.3% reported expansion in the Cardiovascular segment, powered by market share gains in Pulsed Field Ablation (FARAPULSE) and Left Atrial Appendage Closure (WATCHMAN FLX). While management's full-year EPS guidance range ($3.28–$3.32) was slightly conservative relative to consensus estimates ($3.36), the underlying operational engine remains top-tier across medtech.
- Net sales of $5.442B beat consensus estimates ($5.37B) with +7.0% organic sales growth.
- Adjusted EPS of $0.86 exceeded consensus ($0.83) by +3.6%, demonstrating operating margin expansion.
- Cardiovascular division ($3.58B) delivered high organic growth driven by procedural expansion in EP and Structural Heart.
- Full-year EPS guidance ($3.28–$3.32) incorporates prudent macro and FX buffering.
